The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo

International Journal of Oncology

Volumn 45, Issue 2, 2014, Pages 804-812

  Xie, GuI'E ^a   Tang, Hongping ^b   Wu, Shaoqing ^a   Chen, Jingsong ^a   Liu, Jiangwen ^c   Liao, Can ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Shenzhen Maternity amp Child Healthcare Hospital   (China)

^c SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Apoptosis; Breast cancer; Cyclin dependent kinases; Mcl 1; SNS 032; X linked inhibitor of apoptosis protein

Indexed keywords

CASPASE 3; CASPASE 9; MESSENGER RNA; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 8; PROCASPASE 9; PROTEIN BCL 2; PROTEIN MCL 1; RNA 18S; RNA POLYMERASE II; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 2; MCL1 PROTEIN, HUMAN; MYELOID LEUKEMIA FACTOR 1; N-(5-(((5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL)METHYL)THIO)-2-THIAZOLYL)-4-PIPERIDINECARBOXAMIDE; OXAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; XIAP PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NICK END LABELING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RNA SYNTHESIS; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECTS; FEMALE; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 2; FEMALE; HETEROGRAFTS; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; MICE, NUDE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; OXAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; THIAZOLES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84902602224     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2467     Document Type: Article

References (43)

1. Friedenreich CM: Physical activity and breast cancer: review of the epidemiologic evidence and biologic mechanisms. Recent Results Cancer Res 188: 125-139, 2011.
2. Jafaar ZM, Litchfield LM, Ivanova MM, Radde BN, Al-Rayyan N and Klinge CM: β-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression. Int J Oncol 44:1365-1375, 2014.
3. Perez EA: Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 114: 195-201, 2009.
4. Gallorini M, Cataldi A and di Giacomo V: Cyclin-dependent kinase modulators and cancer therapy. BioDrugs 26: 377-391, 2012.
5. Canavese M, Santo L and Raje N: Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther 13: 451-457, 2012.
6. Peterlin BM and Price DH: Controlling the elongation phase of transcription with P-TEFb. Mol Cell 23: 297-305, 2006. (Pubitemid 44128850)
7. Larochelle S, Amat R, Glover-Cutter K, et al: Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol 19: 1108-1115, 2012.
8. Cho SJ, Kim YJ, Surh YJ, Kim BM and Lee SK: Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J Biol Chem 286: 19662-19671, 2011.
9. Wang S and Fischer PM: Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 29: 302-313, 2008.
10. Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566, 2009.
11. Diaz-Padilla I, Siu LL and Duran I: Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Invest New Drugs 27: 586-594, 2009.
12. Liu X, Shi S, Lam F, Pepper C, Fischer PM and Wang S: CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. Int J Cancer 130: 1216-1226, 2012.
13. Shapiro GI: Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 10: S4270-S4275, 2004.
14. Wang LM and Ren DM: Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem 10: 1058-1070, 2012.
15. Gojo I, Zhang B and Fenton RG: The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8: 3527-3538, 2002. (Pubitemid 35340731)
16. Wittmann S, Bali P, Donapaty S, et al: Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 63: 93-99, 2003. (Pubitemid 36070425)
17. Conroy A, Stockett DE, Walker D, et al: SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 64: 723-732, 2009.
18. Chen R, Wierda WG, Chubb S, et al: Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113: 4637-4645, 2009.
19. Xie G, Zhu X, Li Q, et al: SZ-685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathway. Br J Pharmacol 159: 689-697, 2010.
20. Blagosklonny MV, Alvarez M, Fojo A and Neckers LM: Bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. Leuk Res 20: 101-107, 1996. (Pubitemid 26107308)
21. Du Y, Shi A, Han B, et al: COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro. Int J Oncol 44: 1385-1393, 2014.
22. Riggins RB, Schrecengost RS, Guerrero MS and Bouton AH: Pathways to tamoxifen resistance. Cancer Lett 256: 1-24, 2007. (Pubitemid 47333324)
23. Zhang B, Zhang X, Tang B, Zheng P and Zhang Y: Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression. Breast Cancer Res Treat 136: 399-406, 2012.
24. Núñez M, Medina V, Cricco G, et al: Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231. BMC Pharmacol Toxicol 14: 6, 2013.
25. Jordan VC and Brodie AM: Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72: 7-25, 2007. (Pubitemid 46037765)
26. Dickson MA and Schwartz GK: Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 16: 36-43, 2009.
27. Rizzolio F, Tuccinardi T, Caligiuri I, Lucchetti C and Giordano A: CDK inhibitors: from the bench to clinical trials. Curr Drug Targets 11: 279-290, 2010.
28. McInnes C: Progress in the evaluation of CDK inhibitors as antitumor agents. Drug Discov Today 13: 875-881, 2008.
29. Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166, 2009.
30. Rudek MA, Bauer KS Jr, Lush RM III, et al: Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 37: 1369-1374, 2003. (Pubitemid 37205488)
31. Byrd JC, Peterson BL, Gabrilove J, et al: Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 11: 4176-4181, 2005. (Pubitemid 40791583)
32. Flinn IW, Byrd JC, Bartlett N, et al: Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 29: 1253-1257, 2005. (Pubitemid 41297636)
33. Aklilu M, Kindler HL, Donehower RC, Mani S and Vokes EE: Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 14: 1270-1273, 2003. (Pubitemid 37039054)
34. Christian BA, Grever MR, Byrd JC and Lin TS: Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr Opin Oncol 19: 573-578, 2007. (Pubitemid 47508863)
35. Byrd JC, Lin TS, Dalton JT, et al: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109: 399-404, 2007. (Pubitemid 46105932)
36. Phelps MA, Lin TS, Johnson AJ, et al: Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113: 2637-2645, 2009.
37. Lin TS, Ruppert AS, Johnson AJ, et al: Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27: 6012-6018, 2009.
38. Heath EI, Bible K, Martell RE, Adelman DC and Lorusso PM: A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26: 59-65, 2008.
39. Tong WG, Chen R, Plunkett W, et al: Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 28: 3015-3022, 2010.
40. Naumann K, Schmich K, Jaeger C, Kratz F and Merfort I: Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anticancer agents in pancreatic cancer cell lines. Anticancer Drugs 23: 614-626, 2012.
41. Li QQ, Lee RX, Liang H, Wang G, Li JM, Zhong Y and Reed E: β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol 43: 721-728, 2013.
42. Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S and Dent P: Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther 8: 2084-2096, 2009.
43. Lima RT, Martins LM, Guimarães JE, Sambade C and Vasconcelos MH: Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11: 309-316, 2004. (Pubitemid 38586086)